A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)

• Status: Completed
• Trial end date: 2017-05-15
• Target enrollment: 0
• Participant gender: All

Summary

Assessment in a real situation of the conversion conditions, the efficacy and the safety of the treatment with tacrolimus in renal transplant patients converted from the tacrolimus twice per day form (Prograf®) to the tacrolimus once per day form (Advagraf®) with follow-up at one year.

Analysis of two groups of patients: patients converted from Prograf® to Advagraf® early (during the first 6 months post-transplantation) or late (between 6 and 12 months post-transplantation).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma S.A.S.
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Renal transplant patient for less than one year

• Patient where the conversion from Prograf® to Advagraf® has been decided by the doctor

Exclusion Criteria:

• Patient participating in an interventional clinical trial at the time of inclusion